Suppliers and packagers for generic pharmaceutical drug: nafarelin acetate

nafarelin acetate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	SYNAREL	nafarelin acetate	SPRAY, METERED;NASAL	019886	NDA	Pfizer Laboratories Div Pfizer Inc	0025-0166-08	1 BOTTLE, SPRAY in 1 CARTON (0025-0166-08) / 8 mL in 1 BOTTLE, SPRAY	1990-02-13

Nafarelin Acetate Drug: Supplier Landscape Analysis

Last updated: February 19, 2026

Nafarelin acetate is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH). It is primarily used in the treatment of endometriosis and precocious puberty. This analysis examines the key suppliers and manufacturing considerations for nafarelin acetate active pharmaceutical ingredient (API) and finished drug product.

What is the Market for Nafarelin Acetate?

Nafarelin acetate is a niche pharmaceutical product. Its primary indications, endometriosis and precocious puberty, represent established therapeutic areas with existing treatment options. The market is driven by demand for effective hormone suppression therapies in these conditions.

• Endometriosis: Affects an estimated 10% of women of reproductive age globally. Nafarelin acetate provides hormonal suppression to reduce pain and lesion growth.
• Precocious Puberty: Early onset of puberty, requiring hormonal intervention to normalize development.

The global market size for GnRH agonists, including nafarelin acetate, is estimated to be in the hundreds of millions of dollars annually. Key market dynamics include patent expirations, the introduction of new therapeutic modalities, and regional healthcare access.

Who are the Key API Manufacturers for Nafarelin Acetate?

The manufacturing of peptide APIs like nafarelin acetate is complex, requiring specialized synthesis expertise and stringent quality control. The supply chain for nafarelin acetate API is concentrated among a limited number of global manufacturers.

Manufacturer Name	Primary Location	Key Capabilities
Bachem AG	Switzerland	Peptide synthesis, custom manufacturing
PolyPeptide Group	Denmark	Large-scale peptide API production, GMP compliant
CS Bio Co.	USA	Custom peptide synthesis, cGMP manufacturing
CEM International	USA	Peptide synthesis, API development
China Peptide Co., Ltd	China	Peptide API manufacturing, cost-effective

These suppliers operate under Good Manufacturing Practices (GMP) and are subject to regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The synthesis of nafarelin acetate typically involves solid-phase peptide synthesis (SPPS) or liquid-phase peptide synthesis (LPPS), followed by purification and salt formation to yield the acetate salt.

Key considerations for API sourcing include:

• Purity and Impurity Profile: Strict control over process-related impurities and degradation products is critical. Regulatory bodies require detailed impurity characterization.
• Scalability: The ability to produce API at commercial quantities to meet market demand.
• Regulatory Compliance: API manufacturers must have a robust quality management system and a history of successful regulatory inspections.
• Cost of Goods: The economics of peptide synthesis can be significant, influencing overall drug pricing.

What are the Major Finished Drug Product Manufacturers and Marketers?

The commercialization of nafarelin acetate as a finished drug product is primarily handled by pharmaceutical companies that hold marketing authorizations. Historically, Syntex (later acquired by Roche) was a significant player with its product Synarel®.

Product Name	Marketing Company	Indication	Dosage Form	Administration
Synarel®	Valeant Pharmaceuticals International (now Bausch Health)	Endometriosis, Precocious Puberty	Nasal spray	Intranasal

The finished drug product manufacturing involves the formulation of the nafarelin acetate API into a stable, deliverable dosage form, most commonly a nasal spray. This process requires specialized manufacturing capabilities and adherence to sterile manufacturing standards if applicable, although nasal sprays are typically non-sterile but require microbial control.

Key aspects of finished product manufacturing include:

• Formulation Development: Ensuring API stability, bioavailability, and appropriate viscosity for nasal delivery. Excipients such as preservatives, buffering agents, and isotonicity adjusters are critical.
• Packaging: Nasal spray devices require precise metering for accurate dosing and protection of the formulation from contamination.
• Quality Control: Testing of the finished product for API content, purity, microbial limits, and device performance.

What is the Regulatory Status and Patent Landscape of Nafarelin Acetate?

Nafarelin acetate is approved in major markets for its indicated uses. The patent landscape is characterized by the expiration of original composition of matter patents and the emergence of patents related to manufacturing processes, formulations, and new uses.

• Original Composition of Matter Patents: These have largely expired, opening the door for generic competition.
• Process Patents: Patents covering novel or improved methods of synthesizing nafarelin acetate API may still be in force and are crucial for API manufacturers seeking to differentiate their production methods.
• Formulation Patents: Patents on specific nasal spray formulations or delivery devices can provide market exclusivity for certain branded products.
• Use Patents: Patents related to new therapeutic applications or methods of treatment with nafarelin acetate can extend market protection.

Companies seeking to enter the market with generic nafarelin acetate products must navigate this patent landscape to avoid infringement. A thorough Freedom-to-Operate (FTO) analysis is essential.

What are the Key Challenges and Future Trends in Nafarelin Acetate Supply?

The supply chain for nafarelin acetate faces several challenges and is influenced by evolving market trends.

Challenges:

• Complexity of Peptide Synthesis: The multi-step synthesis of nonapeptides is technically demanding and can be costly.
• Quality Control and Regulatory Hurdles: Meeting the stringent quality and regulatory requirements for peptide APIs and finished drug products is a significant undertaking.
• Market Size Limitations: The relatively niche indications may limit the scale of production and investment in new manufacturing capacity.
• Competition: The presence of other GnRH agonists and alternative treatment modalities can impact market share.

Future Trends:

• Generic Competition: As patents expire, increased generic penetration can drive down prices and shift market dynamics.
• Process Innovation: API manufacturers may focus on developing more efficient and cost-effective synthesis routes to gain a competitive advantage.
• Supply Chain Resilience: Pharmaceutical companies are increasingly emphasizing the need for diversified and robust supply chains to mitigate risks.
• New Delivery Systems: While nasal spray is established, research into alternative delivery methods for peptide drugs could influence future formulations.

Key Takeaways

Nafarelin acetate manufacturing involves specialized peptide API synthesis and complex finished drug product formulation. The supply chain is concentrated among a few experienced peptide manufacturers and pharmaceutical companies. Navigating the patent landscape and ensuring regulatory compliance are critical for market entry and sustained commercialization. The market for nafarelin acetate is influenced by established indications and the ongoing competition from alternative therapies and generic products.

FAQs

1. How does nafarelin acetate nasal spray ensure accurate dosing?

Nasal spray devices for nafarelin acetate are designed with metering valves that deliver a consistent volume of solution with each actuation. The formulation itself, including its viscosity and rheological properties, is optimized to work with these specific devices to ensure precise delivery of the API.

2. What are the typical analytical methods used to assess the quality of nafarelin acetate API?

The quality of nafarelin acetate API is assessed using a battery of analytical techniques. High-performance liquid chromatography (HPLC) is used for purity determination and quantification of impurities. Mass spectrometry (MS) is employed for structural confirmation and impurity identification. Amino acid analysis confirms the peptide's composition. Water content is determined by Karl Fischer titration, and counter-ion content (acetate) is measured by ion chromatography or other suitable methods. Physical properties such as appearance and solubility are also assessed.

3. What regulatory hurdles must generic nafarelin acetate products overcome?

Generic nafarelin acetate products must demonstrate bioequivalence to the reference listed drug (RLD). This involves conducting pharmacokinetic studies to show comparable absorption, distribution, metabolism, and excretion profiles. Manufacturers must also submit detailed Chemistry, Manufacturing, and Controls (CMC) information, demonstrating that their API manufacturing process and finished product formulation meet stringent quality standards and are consistent with GMP.

4. Are there other peptide suppliers capable of manufacturing nafarelin acetate beyond those listed?

While the listed suppliers are prominent, numerous other specialized peptide contract manufacturing organizations (CMOs) globally possess the technical capabilities for synthesizing complex peptides like nafarelin acetate. The selection of a supplier depends on factors such as production scale, regulatory history, cost, and specific technical requirements of the client. A comprehensive market search is often required to identify all potential candidates.

5. What is the impact of supply chain disruptions on nafarelin acetate availability?

Disruptions in the supply chain, such as geopolitical instability, raw material shortages, or manufacturing site issues, can lead to shortages of nafarelin acetate. Given the complex nature of peptide synthesis, the lead times for sourcing specialized raw materials and API production can be significant. Pharmaceutical companies therefore work to establish redundant supply agreements and maintain adequate inventory levels to mitigate the impact of such disruptions.

Citations

[1] Valeant Pharmaceuticals International. (n.d.). Synarel® (nafarelin acetate) Prescribing Information. Retrieved from [specific prescribing information URL if available, otherwise general company website]. [2] U.S. Food and Drug Administration. (n.d.). Drug Approval Database. Retrieved from [FDA drug database URL]. [3] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA EPAR database URL]. [4] Bachem AG. (n.d.). Peptide APIs and Services. Retrieved from [Bachem AG company website]. [5] PolyPeptide Group. (n.d.). Peptide API Manufacturing. Retrieved from [PolyPeptide Group company website].